정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1647 | Recruiting | Effectiveness of Niclosamide as Add-on Therapy to the Standard of Care Measures in COVID-19 Management | SARS Pneumonia | Drug: Niclosamide Oral Tablet | Phase 2 | University of Baghdad | OTHER | 150 | All | 18 Years | Ahmed S. Abdulamir, Baghdad, Baghdada, Iraq |
| 1646 | Completed | Effectiveness of Remedesvir in COVID-19 Patients Presenting at Mayo Hospital Lahore | COVID-19 | Drug: Remdesivir Drug: Conventional |
Not Applicable | King Edward Medical University | OTHER | 66 | All | 12 Years | Mayo Hospital, Lahore, Punjab, Pakistan |
| 1645 | Active, not recruiting | Effectiveness of the Adsorbed Vaccine COVID-19 (Coronavac) Among Education and Public Safety Workers With Risk Factors for Severity | Covid19 | Biological: Adsorbed SARS-CoV-2 (inactivated) vaccine | Phase 4 | Fundacao de Medicina Tropical Dr. Heitor Vieira Dourado, Butantan Institute | OTHER | 6233 | All | 18 Years ~ 49 Years | Escola Normal Superior - Universidade do Estado do Amazonas, Manaus, Amazonas, Brazil |
| 1644 | Recruiting | EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF THE HALF DOSE OF THE VACCINE ChadOx1 nCoV-19 (AZD1222) for COVID-19 | SARS-CoV-2 | Biological: Half dose of ChAdOx1 nCoV-19 (AZD1222) Biological: Standard dose of ChAdOx1 nCoV-19 (AZD1222) |
Phase 3 | Federal University of Espirito Santo, Instituto Rene Rachou/Fiocruz, Escola Nacional de Saude Publica Sergio Arouca/Fiocruz, Programa de Computacao Cientifica/Fiocruz, Escola Superior de Ciencias da Santa Casa de Misericordia de Vitoria | OTHER | 29637 | All | 18 Years ~ 49 Years | Federal University of Espirito Santo, Vitoria, Espirito Santo, Brazil |
| 1643 | Completed | Effects in Oxygenation and Hypoxic Pulmonary Vasoconstriction in ARDS Secondary to SARS-CoV2 | SARS-CoV-2 Acute Respiratory Disease | Drug: Effects in oxygenation and hypoxic pulmonary vasoconstriction | Early Phase 1 | Unidad Temporal COVID-19 en Centro Citibanamex | OTHER | 24 | All | 18 Years | Adrian Palacios Chavarria, Mexico City, Mexico |
| 1642 | Completed | Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients | Sars-CoV2 | Biological: COVID-19 Convalescent Plasma (CCP) Biological: Placebo |
Phase 2 | Priscilla Hsue, MD, Blood Systems Research Institute, San Francisco General Hospital | OTHER | 34 | All | 18 Years | San Francisco General Hospital, San Francisco, California, United States UCSF Medical Center at Mount Zion, San Francisco, California, United States University of California, San Francisco Medical Center (Parnassus Campus), San Francisco, California, United States |
| 1641 | Withdrawn | Effects of DPP4 Inhibition on COVID-19 | Type 2 Diabetes | Drug: Linagliptin Drug: Insulin regimen |
Phase 4 | University of Miami | OTHER | 0 | All | 18 Years | University of Miami, Miami, Florida, United States |